Olomorasib Administration Methods for Healthy Subjects

This trial examines how olomorasib, a new treatment, enters the bloodstream when administered in different ways. Researchers aim to determine the most effective method and monitor for any side effects. Participants must stay at the study site for a week during the trial. This trial suits healthy individuals who can commit to a 7-night stay and have no serious medical conditions. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the unique opportunity to be among the first to receive this new treatment.

Research has shown that olomorasib is generally well-tolerated. The most common mild side effects included diarrhea and changes in liver function tests. Specifically, 31% of participants experienced diarrhea, while 26% and 24% showed increased levels of ALT and AST, respectively, which indicate liver health. Notably, only 1% of participants discontinued olomorasib due to side effects. This suggests that olomorasib is relatively safe, with manageable side effects for most people.¹²³⁴⁵

Olomorasib is unique because researchers are exploring different administration methods to optimize its effectiveness and safety. Unlike other treatments that might focus on intravenous or topical applications, Olomorasib is administered orally, which could enhance patient convenience and adherence. This trial could reveal insights into how different oral formulations impact absorption and efficacy, potentially leading to improved therapeutic outcomes. Researchers are excited about this trial as it could pave the way for more patient-friendly treatment options without compromising on the effectiveness.

Research has shown that olomorasib may help treat certain cancers with a specific genetic change called KRAS G12C. In lung cancer patients with this mutation, olomorasib shrank tumors in 77% of cases. When combined with other cancer treatments like cetuximab, the overall response rate was 45%, and disease control reached 92%. These results suggest that olomorasib could effectively manage cancers with the KRAS G12C mutation, though further research is needed to fully understand its potential. In this trial, researchers are studying olomorasib in healthy subjects to evaluate different administration methods.⁶⁷⁸⁹¹⁰